| Description: |
Nicole Princic,1 Eleanor Faherty,2 Meghan Moynihan,1 Caroline Henriques,2 Sandhya Mehta1 1Data Research & Analytics, Real World Data, MarketScan by Merative, Ann Arbor, MI, USA; 2HEOR & RWE, US Medical Affairs, Daiichi Sankyo, Inc., Basking Ridge, NJ, USACorrespondence: Sandhya Mehta, Daiichi Sankyo, Inc., 211 Mt. Airy Road, Basking Ridge, NJ, 07920, USA, Tel +1 908 992 6400, Email sandhya.mehta@daiichisankyo.comPurpose: This study aimed to assess neoadjuvant (neo), post-neo, and adjuvant (adj) treatment (tx) patterns, recurrence rates, and the impact of recurrence timing on the cumulative cost burden among HER2+ early breast cancer (eBC) patients.Methods: Merative™ MarketScan® Databases were used to identify adults newly diagnosed with eBC between 1/1/2017-9/30/2022 with ≥ 1 HER2 targeted treatment following BC date. Surgery within a year of the BC date delineated neo and post-neo/adj periods before and after the surgery date. Recurrence was reported during the post-surgery period and was defined as evidence of additional chemotherapy treatment, metastasis, or end-of-life care. Generalized linear model (GLM) (gamma distribution and log link) was used to assess the impact of disease recurrence on cumulative 3-year total all-cause costs during the post-surgery period.Results: A total of 3745 patients with HER2+ eBC were included in the study (mean age 53.7 yrs): 57.4% (n=2151) with adj tx only, 40.2% (n=1504) with neo and post-neo tx, 1.9% (n=70) with surgery only, and 0.5% (n=20) neo tx only. During follow-up (median duration post-surgery: 2 years), the rate of first recurrence was highest for surgery only (70.0%) and similar for adj only (16.0%) and neo and post-neo tx (14.3%) cohorts. GLM showed that the cumulative cost burden following surgery was higher among patients who experienced the first recurrence in < 12 months vs no recurrence ($348,834 vs $265,279). Patients with chemo only as adj tx had a higher cumulative cost burden (Risk Ratio [RR] 1.28; p ... |